Mesoblast Limited (ASX:MSB)
2.450
-0.040 (-1.61%)
Jul 30, 2025, 4:10 PM AEST
Mesoblast Revenue
Mesoblast had revenue of $3.16M USD in the half year ending December 31, 2024, a decrease of -7.77%. This brings the company's revenue in the last twelve months to $5.67M, down -24.07% year-over-year. In the fiscal year ending June 30, 2024, Mesoblast had annual revenue of $5.90M, down -21.32%.
Revenue (ttm)
$5.67M
Revenue Growth
-24.07%
P/S Ratio
347.71
Revenue / Employee
$77.67K
Employees
73
Market Cap
3.19B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 24.61B |
Pro Medicus | 184.58M |
Cochlear | 2.31B |
Sonic Healthcare | 9.33B |
Ramsay Health Care | 17.12B |
Telix Pharmaceuticals | 783.21M |
Ansell | 3.00B |
Regis Healthcare | 1.10B |
Mesoblast News
- 12 days ago - Mesoblast shares soar 35pc on strong cell therapy sales data - The Australian Financial Review
- 12 days ago - Successful Commercial Launch of Ryoncil® - Benzinga
- 12 days ago - Successful Commercial Launch of Ryoncil® - GlobeNewsWire
- 12 days ago - ASX 200 LIVE: ASX 200 at record; Mesoblast soars 30pc on sales boost - The Australian Financial Review
- 22 days ago - Mesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade) - Seeking Alpha
- 4 weeks ago - Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday - Benzinga
- 4 weeks ago - Mesoblast, FDA agree on marketing application for cell therapy - Seeking Alpha
- 4 weeks ago - Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Benzinga